Breakthrough Status for Xerostomia Therapy; $200M AI JV and Lilly Ocular Deal
FDA granted Breakthrough designation for MeiraGTx’s AAV2-hAQP1 treating Grade 2/3 radiation-induced xerostomia, with final Phase 2 patients enrolling and a program update scheduled for April 16. The company secured $200 million upfront and up to $230 million via a Hologen AI JV for its AAV-GAD Parkinson’s program and granted Lilly exclusive global rights to AAV-AIPL1.
1. FDA Breakthrough Designation and Phase 2 Program
FDA designated AAV2-hAQP1 as Breakthrough Therapy for Grade 2/3 radiation-induced xerostomia, based on three-year Phase 1 data. Final patients are enrolling in the Phase 2 AQUAx2 study (NCT05926765), with topline data expected 12 months after last patient treatment and BLA filing targeted in H1 2027.
2. Hologen Neuro AI Joint Venture
MeiraGTx formed Hologen Neuro AI Ltd with Hologen AI, receiving $200 million upfront and up to $230 million more to fund AAV-GAD development for Parkinson’s disease. MeiraGTx holds 30% of the JV, leading clinical development, and expects to launch a pivotal Phase 3 study within months at global centers.
3. Eli Lilly Collaboration on Ocular Programs
MeiraGTx granted Eli Lilly exclusive global rights to its AAV-AIPL1 gene therapy for LCA4, plus two preclinical ocular programs, intravitreal capsids, bespoke promoters and certain riboswitch platform rights for ocular applications. Lilly will pursue regulatory approvals and global commercialization.
4. Riboswitch Platform and Financial Update
MeiraGTx advanced its riboswitch platform toward an IND for the Ribo-leptin program, demonstrating durable control in animal models out to 19 months and promising neuropathic pain data. The company reported Q4 and full-year 2025 results alongside these operational milestones, highlighting strengthened non-dilutive financing.